Lecigon intestinal gel controls Parkinson’s motor symptoms: Study

Lecigon, an intestinal gel combining levodopa, entacapone, and carbidopa, helps manage motor symptoms in people with advanced Parkinson’s disease. A European study found that Lecigon improved symptom control, sleep, and quality of life over 12 months. The treatment is approved in parts of Europe and Australia but not in the U.S. How Lecigon Works Delivered via a small tube into the intestines using a wearable pump, Lecigon provides continuous medication, reducing motor fluctuations. Unlike Duopa/Duodopa, Lecigon includes entacapone, which enhances levodopa’s availability, allowing for a lower dose and a smaller, lighter pump. Study Findings The ELEGANCE study (NCT05043103) followed 167 participants for up to a year. Before starting Lecigon, they experienced over five daily hours in an "off" state. Within six months, this was reduced by more than three hours, and the benefits lasted up to a year. Lecigon also decreased dyskinesia and improved daily function, as measured by standard Parkinson’s disease rating scales. Improved Quality of Life Participants reported better sleep and high satisfaction with the treatment. Side effects were mostly related to the procedure or device, with no new safety concerns. Looking Ahead Researchers suggest Lecigon may benefit individuals earlier in their Parkinson’s journey, rather than being reserved for late-stage care. As more data emerge, its role in managing motor symptoms will become clearer.